Pharma BD Deal Intelligence
Pfizer expensed $1.4B upfront, then gave away half the pipeline for $10M three years later — a textbook value-destroying anti-infectives bet
Full analysis, sources & comparables →Coverage framed the acquisition positively, highlighting the strategic value of Vicuron's two FDA-filed anti-infectives (anidulafungin and dalbavancin) and…
CEO Hank McKinnell: 'By acquiring Vicuron, we can help bring two very important new medicines to patients around the world,' building on Pfizer's experience in…
Pfizer announced it would withdraw global marketing applications for dalbavancin and run an additional Phase 3 trial after regulatory feedback - a setback for…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Announced mid-June 2004; $29.10/share cash; anti-infectives anidulafungin, dalbavancin; closed Sep 14 2005
Pfizer expensed $1.4B upfront, then gave away half the pipeline for $10M three years later — a textbook value-destroying anti-infectives bet
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Vicuron Pharmaceuticals Inc. (this deal) | 2004 | $1.9B | 26 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2004 deals · Pfizer Inc. deals